Radiofrequency Ablation for the Treatment of Large Symptomatic Heterotopic Gastric Mucosa

Not Applicable

Brief Summary: The heterotopic gastric mucosa found in the cervical esophagus was first described in 1805 and affects 10-15% of individuals undergoing esophagogastroduodenoscopy. It leads to laryngopharyngeal reflux (LPR), which causes symptoms like globus sensation, hoarseness and chronic cough. The Reflux Symptom Index (RSI) that ranges from 0-45 measures LPR. Scores greater than 13 are considered to be pathologic. Currently, patients that suffer from symptoms of LPR and present with a heterotopic gastric mucosa are routinely offered radiofrequency ablation (RFA) as curative treatment. Up to now, around 40 patients were already treated at the department of Surgery with 90% histologic eradication rates after 2 treatment sessions and no reported serious adverse event. Nevertheless, the placebo effect could also be responsible for perception of improving symptoms. Therefore, this prospective sham-controlled trial was designed to exclude the placebo effect. As the device is already approved and routinely used for focal ablation safety data are already available. Up to now, there were no major adverse events, whereas only 10% of patients describe a sensation of irritated throat that dissolves within the first three days after treatment.

Recruitment & Eligibility

Inclusion Criteria

Histological proven presence of heterotopic gastric mucosa,
pathologic Reflux Symptom Index (>25)
age: 18-70
presence of symptoms > 6 months,
no effect on the Reflux Symptom Index to 12 weeks of standard dose proton pump inhibitor treatment
negative symptom correlation for symptoms with reflux events in ambulatory pH monitoring

Exclusion Criteria

Arm && Interventions

Group	Intervention	Description
treatment arm	Radiofrequency ablation	Patients with symptomatic large hetertotopic gastric mucosa receive an esophagoscopy with radiofrequency ablation (12J/cm2) using the Barrx channel RFA endoscopic catheter (Medtronic)
sham-treatment	esophagoscopy	Patients with symptomatic large heterotopic gastric mucosa receive an esophagoscopy without radiofrequency ablation under sedation

Primary Outcome Measures

Name	Time	Method
Normalization of the Reflux Symptom Index	6 months after first RFA treatment/or sham procedure	Normalization of the Reflux Symptom Index (RSI \<14) after two treatment/sham sessions evaluated 3 months after the second (sham-) treatment (therefore 6 months after the first endoscopy with/without RFA). Proton-pump inhibitors are paused 8 weeks before assessment

Secondary Outcome Measures

Name	Time	Method
Reflux Finding Score	Evaluated at the first intervention at study completion after 6 months	the Reflux Finding Score is measured by using laryngofibroscopy to document potential absence of laryngopharyngeal reflux. The reflux finding score (RFS) represents an objective and validated instrument to analyze physical findings and severity of laryngopharyngeal reflux. An 8-item checklist with excellent inter-observer reliability grades abnormalities documented during laryngoscopy from 0-26 points. The total score is reported and summed from an 8 item checklist providing 0-4 points. Statistically, total scores greater than 7 have a likelihood of 95% to reflect LPR. Higher scores represent worse outcomes.
Histological eradication rate after radiofrequency ablation or sham treatment	6 months after first RFA treatment/or sham procedure	Histologic eradication rate after RFA treatment/sham procedure measured after finalization of RFA (normalization of Reflux Symptom Index/or a maximum of two treatment sessions) or at the time of second sham treatment.
SF-12 quality of life	At enrollment (therefore before ablations or sham treatment) and 6 months after first radiofrequency ablation/sham treatment

Receive instant email notifications about changes in this clinical trial

Receive instant email notifications about changes in this clinical trial